II. Indications
- Peptic Ulcer Disease
- Gastroesophageal Reflux
- Erosive Esophagitis
- Zollinger-Ellison Syndrome
III. Contraindications
- Hypersensitivity to Proton Pump Inhibitors
- Use with caution in severe liver disease
IV. Dosing: Adult
- See Helicobacter Pylori Treatment
- Background
- May take regardless of food timing
- When using for Helicobacter Pylori, take with meals
-
Gastroesophageal Reflux
- Take 20 mg orally daily for 4 to 16 weeks
-
Duodenal Ulcer
- Take 20 mg orally daily for 4 weeks
- Zollinger Ellison Syndrome
- Take 60 mg orally daily (up to twice daily)
V. Dosing: Child
- Age 1 to 11 years
- Weight <15 kg: Give 5 mg orally once daily (maximum 10 mg/day) for up to 8 weeks
- Weight >15 kg: Give 10 mg orally once daily for up to 8 weeks
- Age >=12 years
- Give 20 mg orally daily for up to 8 weeks
VI. Pharmacokinetics
VII. Mechanism
VIII. Adverse Effects:
IX. Precautions
X. Safety
- Pregnancy Category B
- Unknown safety in Lactation
XI. Efficacy
XII. Drug Interactions
XIII. Resources
XIV. References
Images: Related links to external sites (from Bing)
Related Studies
| rabeprazole (on 12/21/2022 at Medicaid.Gov Survey of pharmacy drug pricing) | ||
| RABEPRAZOLE SOD DR 20 MG TAB | Generic | $0.20 each |
| aciphex (on 9/1/2022 at Medicaid.Gov Survey of pharmacy drug pricing) | ||
| ACIPHEX DR 20 MG TABLET | Generic | $0.20 each |
Ontology: rabeprazole (C0378482)
| Definition (MSH) | A 4-(3-methoxypropoxy)-3-methylpyridinyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS. |
| Definition (NCI) | An alpha-pyridylmethylsulfinyl benzimidazole and a selective and irreversible proton pump inhibitor with antisecretory property. Rabeprazole enters the parietal cell and accumulates in the acidic secretory canaliculi where the agent is activated by a proton-catalyzed process that results in the formation of a thiophilic sulfonamide or sulfenic acid. The activated rabeprazole forms covalent bonds with the sulfhydryl amino acids cysteine on the extracellular domain of the proton pump (H+/K+ ATPase) at the secretory surface, thereby inhibiting the transport of hydrogen ions, via exchange with potassium ions, into the gastric lumen. Binding to cysteine 813, in particular, is essential for inhibition of gastric acid production. |
| Concepts | Pharmacologic Substance (T121) , Organic Chemical (T109) |
| MSH | D064750 |
| SnomedCT | 421279008, 422225001 |
| LNC | LP171632-5 |
| English | Rabeprazole (product), Rabeprazole (substance), 2-(((4-(3-Methoxypropoxy)-3-methyl-2-pyridinyl)methyl)sulfinyl)-1H-benzimidazole, RABEprazole, 2-((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methylsulfinyl)-1H-benzimidazole, Rabeprazole, rabeprazole, Rabeprazole [Chemical/Ingredient], RABEPRAZOLE |
| Spanish | rabeprazol (producto), rabeprazol, rabeprazol (sustancia) |
| Czech | Rabeprazol |
| French | Rabéprazole |
| German | Rabeprazol, 2-((4-(3-Methoxypropoxy)-3-methyl-2- pyridyl)methylsulfinyl)benzimidazol, Rabeprazolum |
| Italian | Rabeprazolo |
| Russian | PARIET, ПАРИЕТ, DEKSRABEPRAZOL, LY-307640, АЦИФЕКС, ATSIFEKS, РАБЕПРАЗОЛ, E 3810, RABEPRAZOL, ДЕКСРАБЕПРАЗОЛ |
Ontology: Aciphex (C0875952)
| Concepts | Pharmacologic Substance (T121) , Organic Chemical (T109) |
| MSH | D064750 |
| English | aciphex, AcipHex, Aciphex |
